February 2020 Vol 6 No 1
Issue Introductions
Hello everyone and welcome to our February 2020 issue of CONQUER: the patient voice! Once again, we have packed many articles into this new issue to empower you with information, provide hope through inspirational stories from others, and perhaps help you look at the world with a different perspective.
Infusion of HopePatient Stories
Cancer survivor Tricia Tennesen recounts her spirit-lifting experience with a group of survivors on a nature retreat that involved fly-fishing, which offered her a “path to spirituality without doctrine or dogma.”
Patient Stories
By Gail Silver
Julie Silver ran into many “bumps in the road” after she was diagnosed with stage IV ovarian cancer. Despite many difficulties along the way, today her life is filled with gratitude and appreciation.
Family Members
By Paul Kidwell
Paul Kidwell shares his devastating experience at a family gathering for his 31-year-old nephew, who was diagnosed with stage IV colorectal cancer at age 25 and had only weeks to live.
Immunotherapy
When you’re diagnosed with cancer, it’s very common to feel that your body has failed you.
Multiple Myeloma
Dr. Castillo discussed this topic at the National Comprehensive Cancer Network (NCCN) 2019 Hematologic Malignancies annual meeting, explaining how to approach this challenge in the face of recent advances in multiple myeloma treatment.
MesotheliomaSurvivorship
Emily Ward was diagnosed with mesothelioma, a type of cancer usually associated with men who are exposed to asbestos. After working as a nurse for more than 40 years, her surprising diagnosis led to a search for the best care possible.
Breast Cancer
A new and important study showed that the use of hair dyes and chemical straighteners may significantly increase a woman’s risk of breast cancer, especially for African-American women.
Leukemia
By Dana Taylor
Calquence, a new-generation targeted therapy recently approved for the treatment of CLL, has shown good results in a 3-drug combination therapy.
Leukemia
By Dana Taylor
In November 2019, the FDA approved the third Bruton tyrosine kinase (BTK) inhibitor, Brukinsa (zanubrutinib)...
- 1
- 2
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17